Novavax (NVAX) ended November at $1.21. The stock trades a few pennies from the 52-week low of $1.16.
If the beleaguered biotech holds at these lows, traders have an opportunity to dip their toes into the stock. Funding remains a concern, but Novavax will have some major catalysts in 2017 that could reward shareholders. For the next few weeks, tax-loss selling will depress the stock before providing an eventual opportunity as December comes to a close..
Disclosure: No position